Hippocampal Avoidance and Memantine for Whole-Brain Radiotherapy

Long-Term Follow-Up Warranted

Andratschke, N.; Belderbos, J.; Mayinger, M.; Schagen, S.B.; De Ruysscher, D.

DOI
10.1200/JCO.20.00747

Publication date
2020

Document Version
Final published version

Published in
Journal of Clinical Oncology

Citation for published version (APA):

General rights
It is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), other than for strictly personal, individual use, unless the work is under an open content license (like Creative Commons).

Disclaimer/Complaints regulations
If you believe that digital publication of certain material infringes any of your rights or (privacy) interests, please let the Library know, stating your reasons. In case of a legitimate complaint, the Library will make the material inaccessible and/or remove it from the website. Please Ask the Library: https://uba.uva.nl/en/contact, or a letter to: Library of the University of Amsterdam, Secretariat, Singel 425, 1012 WP Amsterdam, The Netherlands. You will be contacted as soon as possible.
Hippocampal Avoidance and Memantine for Whole-Brain Radiotherapy: Long-Term Follow-Up Warranted

TO THE EDITOR:

In their recent study published in Journal of Clinical Oncology, Brown et al. integrated technology improvements and radiobiology-based normal tissue protection research into a large, prospective, randomized trial, which makes it an important contribution to the field of radiation oncology. It is a blueprint example of translating initial biology-based hypotheses through stepwise early-phase clinical investigations into a complex randomized trial that yields a positive result. Nevertheless, with all this euphoria, we would like to step back a bit and highlight a few key points that would need clarification in the context of the trial’s results before we can really adopt hippocampal avoidance whole-brain radiotherapy (HA-WBRT) in combination with memantine as a new standard of care for patients with newly diagnosed brain metastases as advocated by the authors.

First, we acknowledge that HA may have an impact on neurocognition as observed initially by Gondi et al., although the major effect is seen largely in the short term, and long-term effects are basically unknown. Only 41% of participants completed the Hopkins Verbal Learning Test-Revised (HVLT-R) at 4 months, and median survival of patients alive was only 7.9 months. Thus, most patients will not benefit from the treatment, and no clear conclusion on long-term effects can be made. Second, although the difference in the individual parameters looks impressive, the overall neurocognitive failure is still high in the HA-WBRT plus memantine arm (60% at 6 months).

Third, HA as recommended by the treatment protocol comes at a cost when looking at the maximum doses to the brain: 133% (40 Gy) was allowed to < 2% of the planning target volume (60 Gy biologically effective dose, α/β 2 Gy). While considering these high doses, we are concerned that with long-term follow-up, microvascular changes and cortical thinning may be observed accompanied by long-term neurocognitive impairment. Table A1 of the Data Supplement lists the dose-volume analysis of the tumor volume and organs a risk, with unspecified acceptable variation in 26.3% and 48.6%, respectively, which leaves the maximum dose delivered to the brain and hippocampi unclear.

Fourth, we have published a study on an automated treatment planning method to significantly reduce the overall brain dose compared with RTOG 09. Still, we detected—even in the setting of prophylactic cranial irradiation (PCI) and lower dose compared with therapeutic WBRT—significantly more leukoencephalopathy when HA was used compared with simple, straightforward lateral opposed fields.

Fifth, the authors chose a nonspecific primary end point (time to cognitive failure on any neuropsychological test) to assess the efficacy of a specific (ie, HA) intervention without providing a theoretical rationale about the potential benefits on non–hippocampal-dependent functions. Furthermore, post hoc, the authors do not provide explanations for the nonspecific beneficial effects and miss, as such, the opportunity to have their findings properly understood.

Finally, another factor of uncertainty is whether there is a very steep dose-response curve with regard to neurocognitive effects. Two trials of prophylactic WBRT may shed some light on this question: the HA-PCI trial (ClinicalTrials.gov identifier: NCT01780675) and the NVALT11 trial. The NVALT11 trial investigated PCI without hippocampal sparing in patients with non–small-cell lung cancer and showed a higher percentage of physician-rated neurocognitive impairment in the PCI arm compared with the observation arm. On the other hand, the multicenter randomized phase III HA-PCI trial did not support a beneficial effect of hippocampus-sparing PCI over PCI in patients with small-cell lung cancer. The trial showed no difference in the percentage of patients who showed a decline of the hippocampus-specific HVLT-R at 4 months. In consideration of these caveats, we encourage waiting for long-term neurocognitive and imaging results before we advocate HA-WBRT in combination with memantine as standard of care in patients with good performance.

Nicolaus Andratschke, MD
Department of Radiation Oncology, University Hospital and University of Zurich, Zurich, Switzerland
José Belderbos, MD, PhD
Department of Radiation Oncology, the Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands
Michael Mayinger, MD
Department of Radiation Oncology, University Hospital and University of Zurich, Zurich, Switzerland
Sanne B. Schagen, PhD
Division of Psychosocial Research and Epidemiology, the Netherlands Cancer Institute, Amsterdam, The Netherlands
Dirk De Ruysscher, MD, PhD
Department of Radiotherapy (Maastricht), Maastricht University Medical Center, GROW Research Institute, Maastricht, the Netherlands

AUTHORS’ DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST AND DATA AVAILABILITY STATEMENT
Disclosures provided by the authors and data availability statement (if applicable) are available with this article at DOI https://doi.org/10.1200/JCO.20.00747.

REFERENCES

DOI: https://doi.org/10.1200/JCO.20.00747; Published at ascopubs.org/journal/jco on August 12, 2020.
AUTHORS’ DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST

Hippocampal Avoidance and Memantine for Whole-Brain Radiotherapy: Long-Term Follow-Up Warranted

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO’s conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/jco/authors/author-center.

Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments).

Nicolaus Andratschke
Honoraria: Debiopharm Group, AstraZeneca
Research Funding: ViewRay (Inst), Brainlab (Inst)
Travel, Accommodations, Expenses: ViewRay

Dirk De Ruysscher
Consulting or Advisory Role: Bristol Myers Squibb (Inst), AstraZeneca (Inst), Merck Serono (Inst), Celgene (Inst), Roche (Inst), Genentech (Inst), Seattle Genetics (Inst), MSD Oncology (Inst), Philips Healthcare (Inst), Olink Bioscience (Inst)
Research Funding: Bristol Myers Squibb (Inst), AstraZeneca (Inst), Philips Research (Inst), Olink Bioscience (Inst)

No other potential conflicts of interest were reported.